Here are the S-1 registration statements from Nexentis Technologies Inc. (NXTS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow NXTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTS filings page.
Nexentis Technologies Inc. filed a resale registration covering up to 2,572,874 shares of common stock for existing investors. The shares are issuable upon exercise of three warrant classes: 311,876 First PIPE Warrants, 410,998 Second PIPE Warrants, and 1,850,000 Facility Warrant shares. Nexentis will not receive proceeds from selling stockholder resales, but could receive up to $6.0 million in gross proceeds if all warrants are exercised for cash; the warrants also allow cashless exercise in some circumstances.
Shares outstanding were 1,453,333 as of July 10, 2026, and would rise to 4,026,207 if all registered warrants are exercised. The company operates in biotechnology through wholly owned MitoCareX Bio Ltd., developing small-molecule therapies targeting mitochondrial SLC25A proteins for cancers such as non-small cell lung and pancreatic cancer, and in solar energy via a 70% interest in an Italian PV project joint venture. For 2025, Nexentis reported a net loss attributable to stockholders of $4.0 million and total basic loss per share of $24.71. Auditors highlighted substantial doubt about its ability to continue as a going concern. The company also has a EUR 10,000,000 credit facility with 7% interest tied to the issuance of the Facility Warrant.